Eficacia y seguridad del uso extendido de anticonceptivos orales combinados / Efficacy and safety of extended use of combined oral contraceptives

Los anticonceptivos orales combinados constituyen hoy en día uno de los métodos anticonceptivos más populares a nivel mundial. Su composición consiste en una combinación de análogos de hormonas sexuales femeninas que se administran en bajas dosis diarias, manteniendo constante su concentración sanguínea y evitando de esta forma los cambios en el eje endócrino que estimulan la ovulación. Con el objetivo de recrear los procesos fisiológicos, la mayoría de las formulaciones comprenden un intervalo de 4 a 7 días libres de hormonas en el cual se genera el sangrado por deprivación.A partir de una viñeta clínica en la que una paciente sana desea posponer su hemorragia por deprivación, y tras realizar una búsqueda bibliográfica que prioriza las investigaciones más recientes y de mejor calidad, la autora revisa la evidencia sobre el uso de hormonas sin intervalo libre, especialmente su efectos sobre la eficacia y la incidencia de efectos adversos. (AU)

Nowadays, combined oral contraceptives are one of the most popular contraceptive methods worldwide. Its composition consists of a combination of similar female sex hormones administered in low daily doses, keeping their blood concentration constant and thus avoiding changes in the endocrine axis that stimulate ovulation. In order to recreate physiological processes, most formulations include an interval of 4 to 7 hormone-free days in which withdrawal bleeding occurs.Starting from a clinical vignette in which a healthy patient desires to postpone her withdrawal bleeding, and after conducting a bibliographic search that prioritizes the most recent and best-quality research, the author reviews the evidence about the use of hormones without free interval, especially their effects on efficacy and the incidence of adverse effects. (AU)

Prenatal and pubertal exposure to 17α-ethinylestradiol disrupts folliculogenesis and promotes morphophysiological changes in ovaries of old gerbils (Meriones unguiculatus).

17α-Ethinylestradiol is an endocrine-disrupting chemical that make up most contraceptive pills and can be found in the environment. Exposure to ethinylestradiol in different development periods may promote changes in morphophysiological parameters of reproductive and endocrine organs. Considering that the effects of low doses (15 µg/kg/day) of ethinylestradiol in ovaries from 12-month-old female gerbils (Meriones unguiculatus) were investigated. Four experimental groups used were control (without treatment), EE/PRE (treated from the 18th to the 22nd gestational day), EE/PUB (treated from the 42nd to the 49th day of life), and EE/PRE-PUB (treated in the both periods). The animals were euthanized at 12 months. Testosterone and 17ß-estradiol levels were measured. The ovaries were stained with Hematoxylin and Eosin, Periodic Acid Schiff, and Gomori's Trichome. The follicles, corpus luteum, interstitial gland, lipofuscin, ovarian epithelium, and tunica albuginea were analyzed. Estradiol was higher in EE/PRE and EE/PUB groups, while testosterone was higher only in EE/PUB group. The main changes in follicle count occurred in EE/PUB and EE/PRE-PUB groups, with higher primordial follicle count and lower maturation of follicles. The corpus luteum was more evident in EE/PRE group. No differences were found in atretic follicles count. A higher area occupied by interstitial gland cells and lipofuscin deposit in these cells was noted in EE/PUB and EE/PRE-PUB groups. Higher epithelium height and thicker tunic albuginea were showed in treated groups. These results suggest that exposure to doses of EE2 in prenatal and pubertal periods of the development leads to morphological changes in senile ovaries.

Combined oral contraceptive in female mice causes hyperinsulinemia due to ß-cell hypersecretion and reduction in insulin clearance.

Oral contraception is the most commonly used interventional method in the world. However, several women employ the continuous use of these hormones to avoid pre- and menstruation discomforts. Some studies indicate that oral contraceptives are associated with disturbances in glycemia and the effects of the use of a continuous regime are poorly elucidated. Herein, we evaluated the effects of the continuous administration of a combined oral contraceptive (COC) composed by ethinyl estradiol (EE) and drospirenone (DRSP) on glucose homeostasis in female mice. Adult Swiss mice received 0.6 µg EE and 60 µg DRSP (COC group) or vehicle [control (CTL)] daily by gavage for 35 days. COC treatment had no effect on body weight or adiposity, but increased uterus weight and induced hepatomegaly. Importantly, COC females displayed normal glycemia and glucose tolerance, but hyperinsulinemia and lower plasma C-peptide/insulin ratio, indicating reduced insulin clearance. Furthermore, COC mice displayed reduced protein content of the ß subunit of the insulin receptor (IRß) in the liver. Additionally, pancreatic islets isolated from COC mice secreted more insulin in response to increasing glucose concentrations. This effect was associated with the activity of steroid hormones, since INS-1E cells incubated with EE plus DRSP also secreted more insulin. Therefore, we provide the first evidence that the continuous administration of EE and DRSP lead to hyperinsulinemia, due to enhancement of insulin secretion and the reduction of insulin degradation, which possibly lead to the down-regulation of hepatic IRß. These findings suggest that the continuous administration of COC could cause insulin resistance with the prolongation of treatment.

Acute pancreatitis secondary to oral contraceptive-induced hypertriglyceridemia: a case report.

Hypertriglyceridemia is the third most common cause of acute pancreatitis. Among the causes that lead to secondary hypertriglyceridemia, the use of contraceptive agents is the main reason to be assessed in young women. We report a case of a 31-year-old woman who had suffered two acute pancreatitis episodes secondary to hypertriglyceridemia. In the investigation, the previous medical team indicated a genetic screening before ruling out all secondary causes. LPL, apo CII and apo AV genes were negative for mutations. In the first appointment with us, the patient reported the use of a contraceptive agent for about 2 years. She was instructed to discontinue the drug. After one year of follow-up, her serum triglycerides are within the normal range and a copper intrauterine device was the method chosen by the patient for contraception.

Análise histomorfométrica da artéria aorta de ratas submetidas à administração repetida da associação de etinilestradiol e gestodeno / Histomorphometric analysis of the aorta of rats submitted to repeated administration of association of ethinylestradiol and gestodene

Introdução: Os anticoncepcionais orais vêm sofrendo alterações em suas concentrações de estrogênio e progestogênio, baseando-se no fato de que doses mais baixas estão associadas a menor incidência de alterações metabólicas e de efeitos adversos, como o comprometimento da morfologia e função da artéria aorta. O objetivo deste estudo é avaliar a influência dos anticoncepcionais nas propriedades morfofuncionais da artéria aorta, através do método histoquímico, demonstrando sua utilidade nas análises histopatológicas. Métodos: Para tanto, foram utilizadas 15 ratas divididas em 3 grupos; Grupo controle (GC), cujos animais não receberam tratamento hormonal; Grupo 2 (G2), onde os animais receberam tratamento diário de 15 µg de etinilestradiol + 60 µg de gestodeno; e Grupo 3 (G3), que recebeu 30 µg de etinilestradiol + 75 µg de gestodeno. Após o tratamento, os animais foram eutanasiados e as artérias retiradas para análise histológica. Resultados: Os valores encontrados com a técnica de coloração histológica de hematoxilina e eosina (HE), bem como na coloração específica em histoquímica com Alcian Blue, demonstram que no G3, tratados com uma dosagem superior de hormônio, 8% das ratas tem aumento relevante da espessura de suas artérias, ou seja, superior ao G2, que recebeu dosagem menor de hormônio, e GC, o qual não recebeu nenhum tipo de tratamento. Conclusão: Este estudo demonstra que existem relações entre o espessamento das artérias, de ratas submetidas a dosagens de etinilestradiol e gestodeno, com a grande quantidade de mucopolissacarídeos depositados entre as túnicas das artérias. (AU)

Introduction: Pharmacological development of hormonal contraceptives has been undergoing changes in estrogen and progesterone doses, based on the fact that lower doses are associated with a lower incidence of metabolic changes and adverse effects, such as impairment of morphology and function of the aortic artery. The aim of this study is to evaluate the influence of contraceptives on the morphofunctional properties of the aortic artery, using the histochemical method, demonstrating its usefulness in histopathological analyzes. Methods: For this purpose, 15 rats were divided into 3 groups; Control group (GC), whose animals did not receive hormonal treatment; Group 2 (G2), where the animals received a daily treatment of 15 µg of ethinylestradiol + 60 µg of gestodene; and Group 3 (G3), whose animals received 30 µg of ethinylestradiol + 75 µg of gestodene. After treatment, the animals were sacrificed and the arteries removed for histologic analysis. Results: The values found, with HE measurements and Alcian Blue histochemical staining, showed that in G3, treated with a higher hormone dosage, there are 8% of the rats with a relevant increase in the thickness of their arteries, that is, higher than that of G2, which received lower dosage of hormone and that of GC, which received no treatment. Conclusion: This study demonstrates that there are relations between the thickening of the arteries of rats submitted to dosages of ethinylestradiol and gestodene with the great amount of mucopolysaccharides deposited between the tunics of the arteries. (AU)

Distribución de esteroides estrogénicos en plantas de tratamiento de aguas residuales municipales / Distribution of estrogenic steroids in municipal wastewater treatment plants

En la actualidad, existe una preocupación creciente por la presencia de estrógenos en el medio acuático, donde pueden ser introducidos a partir de aguas residuales después de su eliminación incompleta en las plantas de tratamiento. Las aguas residuales sistemáticamente reciben estrógenos naturales y sintéticos, y por lo tanto una comprensión más profunda de la suerte de ellos en el medio ambiente es necesaria. Se evaluaron los niveles de estrógenos en los efluentes de las Plantas de Tratamiento de Aguas Residuales (PTARs) Penha e Ilha do Governador, ambos de tipo convencional de flujo continuo de lodo activado con aireación prolongada. Fue utilizado como el parámetro de determinación de algunos compuestos de interés como estrógenos naturales [estrona (E1), 17β-estradiol (E2), estriol (E3)) y sintéticos (17α-etinilestradiol (EE2)]. Las muestras individuales se recogieron posteriormente al tratamiento de cada PTAR y después de los procedimientos de laboratorio se realizó la determinación de estrógenos basado en la extracción en fase sólida (SPE) y la cromatografía líquida de alta resolución con detector de arreglo de diodos (HPLC-DAD). Las concentraciones fueron de: 0,7 a 5,2 μg/l y de 0,5 a 5,6 de E1; 0,9 a 7,7 y 1,2 a 9,2 μg/l para E2; 2,01 a 6,09 y 1,07 a 4,08 μg/l para EE2 en PTAR Penha y PTAR Ilha do Governador, respectivamente. La capacidad de eliminación de estrógenos fue eficaz, pero denota que la eliminación sistemática de la población es en la actualidad alta. Se recomienda instalar mecanismos para mitigar el consumo exagerado de estas sustancias o implementar una eliminación completa más eficaz.

Currently, there is a growing concern over the presence of estrogens in the aquatic environment, where they can be introduced from wastewater after their incomplete elimination in the treatment plants. Wastewater systematically receives natural and synthetic estrogens, and thus a deeper understanding of the fate of them in the environment is extremely necessary. It was evaluated estrogen levels in the effluent from the Sludge Wastewater Treatment Plants (SWTPs) Penha and Ilha do Governador, both of type conventional continuous-flow activated sludge with extended aeration. The determination of some target compounds as natural estrogens was used as the evaluation parameter [estrone (E1), 17β-estradiol (E2), estriol (E3) and synthetic (17α-ethinylestradiol (EE2)]. Individual samples were collected posterior treatment of each SWTP, and after laboratory procedures, the determination of estrogens was performed by a method based on solid phase extraction (SPE) and high performance liquid chromatography-diode array detector (HPLC-DAD). Concentrations ranged from 0.7 to 5.2 μg/l and from 0.5 to 5.6 for E1; 0.9 to 7.7 and 1.2 to 9.2 μg/l for E2; 2.1 to 6.9 and 1.7 to 4.8 μg/l for EE2 at SWTPs Penha and Ilha do Governador, respectively. The removal capacity of estrogens despite its effectiveness denotes that the systematic elimination by the population is high nowadays and urging mechanisms to mitigate the exaggerated consumption or to implement most effective complete removal.

Tromboembolismo e contracepção hormonal: evidências que orientam o aconselhamento / Thromboembolism and hormonal contraception: scientific evidence that can guide counseling

A evolução da contracepção hormonal permitiu à mulher apoderar-se do controle sobre sua fertilidade e beneficiar-se de efeitos que, além de extrapolarem a contracepção, são igualmente desejados. No entanto, dentre os eventos adversos, a ocorrência de tromboembolismo em usuárias de contracepção hormonal segue sendo uma preocupação em contínua avaliação. Nesse sentido, é necessário estabelecer o real papel dos diferentes contraceptivos hormonais (CH) como fator de risco para trombose. Com esse propósito, essa revisão examina as evidências científicas anteriormente publicadas nas bases de dados Medline, Pubmed e Cochrane, utilizando-se os descritores contraceptivos hormonais e tromboembolismo venoso. Após adequação aos critérios de seleção, foram utilizadas onze revisões sistemáticas ou metanálises publicadas entre 1998 e 2014, que incluíram 145 estudos publicados entre 1982 e 2013. As evidências apontam para maior segurança nas formulações com progestogênio isolado e contraceptivos com etinilestradiol em doses iguais ou menores que 35 mcg associado a progestogênios de 1ª geração ou levonorgestrel. Mais estudos são necessários para determinar o risco de tromboembolismo com as formulações combinadas de estradiol associado ao dienogeste e norgestimato, bem como examinar o impacto das vias transdérmica e oral nas formulações comercializadas no Brasil. Assim, não se recomenda privar mulheres de baixo risco para acidentes tromboembólicos dos benefícios da contracepção hormonal. O aconselhamento deve ponderar o risco de tromboembolismo preexistente, o risco de gravidez não planejada e suas complicações biopsicossociais e a composição do CH.(AU)

The evolution of hormonal contraception has enabled women to take control of their fertility and to benefit from effects that go beyond contraception. However, among the adverse effects, the occurrence of thromboembolism in users of hormonal contraception is a concern that has been evaluated, making it necessary to determine the actual role of different hormonal contraceptives (HC) as a risk factor for thrombosis. With that purpose, it was conducted a review of the scientific evidence published in Medline, Pubmed and Cochrane database using the following keywords: hormonal contraceptives and venous thromboembolism. The current review analysed eleven systematic reviews or meta-analyzes published between 1998 and 2014, bringing together 145 studies published between 1982 and 2013. The evidences point to increased security with formulations with isolated progestins and contraceptives with ethynilestradiol in doses equal to or less than 35 mcg associated with a first generation progestin or levonorgestrel. Additional studies are necessary to determine the risk of thromboembolism of estradiol combined formulations associated with dienogeste and norgestimate, as well as transdermal and oral formulations marketed in Brazil. Thus, it is inappropiate to deprive women at low risk for thromboembolic events from the benefits of hormonal contraception. Counseling should consider the risk of pre-existing thromboembolism, the risk of unplanned pregnancy with its biopsychosocial complications and particular HC composition.(AU)

Efeitos de hormônios esteroides de contraceptivos orais combinados sobre os parâmetros comportamentais de Betta splendens (Regan, 1909) / Effects of steroid hormones from combined oral contraceptives on the behavioral and physiological parameters of Betta splendens (Regan, 1909)

Os hormônios esteroides presentes em várias gerações de contraceptivos orais combinados (COC) podem se apresentar como disruptores endócrinos, produzindo alterações no comportamento e na fisiologia de peixes. Diante disso, o objetivo deste trabalho foi avaliar os efeitos de hormônios esteroides presentes em COC sobre os parâmetros comportamentais de Betta splendens, um peixe ornamental usado na aquariofilia e bastante agressivo. Machos adultos foram observados pelo método ad libitum para confecção do etograma e divididos em cinco grupos, controle e expostos aos hormônios: 17β-estradiol (E2); levonorgestrel e etinilestradiol (LEA - segunda geração de COC); gestodeno e etinilestradiol (GEA - terceira geração de COC); e drospirenona e etinilestradiol (DEA - quarta geração de COC). Os peixes foram expostos por 30 dias à concentração final de 10ng/L. Foram avaliados os comportamentos pelos métodos de varredura instantânea e animal-focal, bem como o consumo de ração. No método varredura, o comportamento descansar apresentou o maior valor (54,4±10,1%) no grupo E2 (P<0,05). Os comportamentos agressivos de carga (16,1±3,6%) e recuar e carga (16,4±5,1%) apresentaram os maiores valores no grupo controle em relação aos demais grupos (P<0,05). Os animais do grupo E2 apresentaram maior frequência de comportamentos inativos (76,1%) comparados aos de outros grupos. O comportamento atípico natação errática não foi observado no grupo controle, mas foi observado nos grupos experimentais. Os grupos E2, LEA, GEA e DEA apresentaram redução nos comportamentos agressivos (10%) quando comparados ao grupo controle pelo método animal-focal. Não foram observadas diferenças na exibição desses comportamentos ao se compararem os animais expostos às diferentes gerações de contraceptivos e no consumo de ração. Pode-se concluir que 17β-estradiol causou mais efeitos aos peixes e que diferentes gerações de COC apresentaram efeitos tóxicos semelhantes em relação aos comportamentos observados.(AU)

The steroid hormones present in many generations of combined oral contraceptives (COC) can act as endocrine disruptors inducing changes in the behavior and physiology of fish. In this context, the aim of this work was to evaluate the effects of steroid hormones present in COC on behavioral parameters of Betta splendes, an aggressive ornamental fish used in the aquariophily. Adult males were observed with the ad libitum method to develop an ethogram and were divided into five groups, Control and exposed to hormones: 17β-estradiol (E2), levonorgestrel and ethinylestradiol (LEA - 2nd COC generation), gestodene and ethinylestradiol (GEA - 3rd COC generation) and drospirenone and ethinylestradiol (DEA - 4th COC Generation). Fish were exposed for 30 days to a final concentration of 10ng/L. The behavior was evaluated by scan sampling and animal-focal methods, and feed intake. In the scan sampling method, the Resting behavior showed the highest value (54.4±10.1%) in E2 group (P<0.05). The aggressive behavior Rush (16.1±3.6%) and Back and Rush (16.4±5.1%) showed the highest values in the control group, compared to the other groups (P<0.05). Animals in the E2 group showed higher frequency of inactive behaviors (76.1%) compared to other groups. Furthermore, the atypical behavior Erratic swimming was not observed in the control group, but it was observed in the experimental groups. The E2, LEA, GEA and DEA groups showed reduction in aggressive behavior (10%) compared to the control group by the animal-focal method. Moreover, no difference was observed in the exhibition of these behaviors and feed intake comparing animals exposed to the different generations of contraceptives. It can be concluded that 17β-estradiol has caused more effects on fish and different generations of COC showed similar toxic effects in the observed behaviors.(AU)

Efeitos de hormônios esteroides de contraceptivos orais combinados sobre os parâmetros comportamentais de Betta splendens (Regan, 1909) / Effects of steroid hormones from combined oral contraceptives on the behavioral and physiological parameters of Betta splendens (Regan, 1909)

Os hormônios esteroides presentes em várias gerações de contraceptivos orais combinados (COC) podem se apresentar como disruptores endócrinos, produzindo alterações no comportamento e na fisiologia de peixes. Diante disso, o objetivo deste trabalho foi avaliar os efeitos de hormônios esteroides presentes em COC sobre os parâmetros comportamentais de Betta splendens, um peixe ornamental usado na aquariofilia e bastante agressivo. Machos adultos foram observados pelo método ad libitum para confecção do etograma e divididos em cinco grupos, controle e expostos aos hormônios: 17β-estradiol (E2); levonorgestrel e etinilestradiol (LEA - segunda geração de COC); gestodeno e etinilestradiol (GEA - terceira geração de COC); e drospirenona e etinilestradiol (DEA - quarta geração de COC). Os peixes foram expostos por 30 dias à concentração final de 10ng/L. Foram avaliados os comportamentos pelos métodos de varredura instantânea e animal-focal, bem como o consumo de ração. No método varredura, o comportamento descansar apresentou o maior valor (54,4±10,1%) no grupo E2 (P<0,05). Os comportamentos agressivos de carga (16,1±3,6%) e recuar e carga (16,4±5,1%) apresentaram os maiores valores no grupo controle em relação aos demais grupos (P<0,05). Os animais do grupo E2 apresentaram maior frequência de comportamentos inativos (76,1%) comparados aos de outros grupos. O comportamento atípico natação errática não foi observado no grupo controle, mas foi observado nos grupos experimentais. Os grupos E2, LEA, GEA e DEA apresentaram redução nos comportamentos agressivos (10%) quando comparados ao grupo controle pelo método animal-focal. Não foram observadas diferenças na exibição desses comportamentos ao se compararem os animais expostos às diferentes gerações de contraceptivos e no consumo de ração. Pode-se concluir que 17β-estradiol causou mais efeitos aos peixes e que diferentes gerações de COC apresentaram efeitos tóxicos semelhantes em relação aos comportamentos observados.

The steroid hormones present in many generations of combined oral contraceptives (COC) can act as endocrine disruptors inducing changes in the behavior and physiology of fish. In this context, the aim of this work was to evaluate the effects of steroid hormones present in COC on behavioral parameters of Betta splendes, an aggressive ornamental fish used in the aquariophily. Adult males were observed with the ad libitum method to develop an ethogram and were divided into five groups, Control and exposed to hormones: 17β-estradiol (E2), levonorgestrel and ethinylestradiol (LEA - 2nd COC generation), gestodene and ethinylestradiol (GEA - 3rd COC generation) and drospirenone and ethinylestradiol (DEA - 4th COC Generation). Fish were exposed for 30 days to a final concentration of 10ng/L. The behavior was evaluated by scan sampling and animal-focal methods, and feed intake. In the scan sampling method, the Resting behavior showed the highest value (54.4±10.1%) in E2 group (P<0.05). The aggressive behavior Rush (16.1±3.6%) and Back and Rush (16.4±5.1%) showed the highest values in the control group, compared to the other groups (P<0.05). Animals in the E2 group showed higher frequency of inactive behaviors (76.1%) compared to other groups. Furthermore, the atypical behavior Erratic swimming was not observed in the control group, but it was observed in the experimental groups. The E2, LEA, GEA and DEA groups showed reduction in aggressive behavior (10%) compared to the control group by the animal-focal method. Moreover, no difference was observed in the exhibition of these behaviors and feed intake comparing animals exposed to the different generations of contraceptives. It can be concluded that 17β-estradiol has caused more effects on fish and different generations of COC showed similar toxic effects in the observed behaviors.

Regulation of the synthetic estrogen 17α-ethinylestradiol in water bodies in Europe, the United States, and Brazil.

The synthetic estrogen 17α-ethinylestradiol, the principal component of oral contraceptives, has been identified as one of the main compounds accounting for adverse effects on the endocrine system in various species. This study aimed to analyze the state-of-the-art in legislation and guidelines for the control of this synthetic estrogen in water bodies in Europe and the United States and to draw a parallel with the Brazilian reality. Countries have generally attempted to expand the regulation and monitoring of certain emerging micropollutants not previously covered by legislation. Europe is more advanced in terms of water quality, while in the United States this estrogen is only regulated in water for human consumption. Brazil still lacks legal provisions or standards for this estrogen, which can be explained by the relatively limited maturity of the country's system for controlling water pollutants.

Regulamentação do estrogênio sintético 17-etinilestradiol em matrizes aquáticas na Europa, Estados Unidos e Brasil / Regulación del estrógeno sintético 17-etinilestradiol en matrices acuáticas en Europa, Estados Unidos y Brasil / Regulation of the synthetic estrogen 17-ethinylestradiol in water bodies in Europe, the United States, and Brazil

O estrogênio sintético 17α-etinilestradiol, principal componente utilizado em formulações de contraceptivos orais, tem sido apontado como um dos principais compostos responsáveis por provocar efeitos adversos no sistema endócrino de várias espécies. O objetivo deste estudo foi analisar o estado da arte dos dispositivos legais e normativos referentes ao controle desse estrogênio sintético nas águas da Europa e dos Estados Unidos, e traçar um paralelo com a realidade brasileira. No geral, os países têm buscado ampliar a regulamentação e monitoramento de alguns micropoluentes emergentes que antes não eram objeto de atenção por parte dos dispositivos legais. A Europa está mais avançada no que tange à qualidade dos corpos hídricos, enquanto que nos Estados Unidos esta substância é alvo de regulamentação apenas para a água destinada ao consumo humano. No Brasil, ainda não há nenhum dispositivo legal ou normativo que aborde esse estrogênio, o que pode ser associado a uma baixa maturidade do sistema brasileiro quanto ao controle de poluentes hídricos.

El estrógeno sintético 17α-etinilestradiol, principal componente utilizado en fórmulas de contraceptivos orales, ha sido apuntado como uno de los principales compuestos responsables por provocar efectos adversos en el sistema endócrino de varias especies. El objetivo de este estudio fue analizar el estado de la cuestión de los dispositivos legales y normativos referentes al control de este estrógeno sintético en las aguas de Europa y de los Estados Unidos, y trazar un paralelo con la realidad brasileña. En general, los países han buscado ampliar la regulación y el monitoreo de algunos microcontaminantes emergentes que antes no eran objeto de atención por parte de los dispositivos legales. Europa está más avanzada en lo que se refiere a la calidad de los cuerpos hídricos, mientras que en los Estados Unidos esta substancia es objeto de regulación solamente para el agua destinada al consumo humano. En Brasil todavía no existe ningún dispositivo legal o normativo que aborde este estrógeno, lo que puede ser asociado a una inmadurez del sistema brasileño respecto al control de contaminantes hídricos.

The synthetic estrogen 17α-ethinylestradiol, the principal component of oral contraceptives, has been identified as one of the main compounds accounting for adverse effects on the endocrine system in various species. This study aimed to analyze the state-of-the-art in legislation and guidelines for the control of this synthetic estrogen in water bodies in Europe and the United States and to draw a parallel with the Brazilian reality. Countries have generally attempted to expand the regulation and monitoring of certain emerging micropollutants not previously covered by legislation. Europe is more advanced in terms of water quality, while in the United States this estrogen is only regulated in water for human consumption. Brazil still lacks legal provisions or standards for this estrogen, which can be explained by the relatively limited maturity of the country's system for controlling water pollutants.

Adenoviral transfer of human aquaporin-1 gene to rat liver improves bile flow in estrogen-induced cholestasis.

Estrogens can cause liver cholestatic disease. As downregulation of hepatocyte canalicular aquaporin-8 (AQP8) water channels has been involved in estrogen-induced bile secretory failure, we tested whether the archetypal water channel AQP1 improves 17α-ethinylestradiol (EE)-induced cholestasis. EE administration to rats reduced bile flow by 50%. A recombinant adenoviral (Ad) vector encoding human AQP1 (hAQP1), AdhAQP1, or a control vector was administered by retrograde bile ductal infusion. Hepatocyte canalicular hAQP1 expression was confirmed by liver immunostaining and immunoblotting in purified membrane fractions. Accordingly, canalicular osmotic water permeability was markedly increased. Bile flow, either basal or bile salt-stimulated was significantly augmented by over 50%. The choleretic efficiency of endogenous bile salts (that is, volume of bile per µmol of excreted bile salt) was significantly increased by 45% without changes in the biliary bile salt composition. Our data suggest that the adenoviral transfer of hAQP1 gene to the livers of EE-induced cholestatic rats improves bile flow by enhancing the AQP-mediated bile salt-induced canalicular water secretion. This novel finding might have potential therapeutic implications for cholestatic diseases.

Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.

This Phase III, uncontrolled, open-label, multicenter study was conducted to investigate the contraceptive efficacy, bleeding pattern, and cycle control of a novel once-a-week contraceptive patch, delivering low-dose ethinyl estradiol (EE) and gestodene (GSD) at the same systemic exposure seen after oral administration of a combined oral contraceptive containing 0.02 mg EE/0.06 mg GSD. Participants were women aged 18 to 35 years, all of whom received the EE/GSD patch for 13 cycles each of 21 treatment days (one patch per week for 3 weeks) followed by a 7-day, patch-free interval. The primary efficacy variable was the occurrence of unintended pregnancies during the study period as assessed by life table analysis and the Pearl Index. Secondary efficacy variables were days with bleeding during four 90-day reference periods and during 1 treatment year, bleeding pattern, and cycle control. The Kaplan-Meier probability of contraceptive protection after 364 treatment days was 98.8% and the adjusted Pearl Index was 0.81. The percentage of participants with intracyclic bleeding/spotting decreased over time, from 11.4% to 6.8% in cycles 1 and 12, respectively. Almost all participants (range: 90.8%-97.6%) experienced withdrawal bleeding across the study period. Compliance was very high (mean: 97.9%; median: 100%). The most frequent adverse events were headache (9.5%) and application site reaction (8.5%); no clinically significant safety concerns were observed. Results suggest the EE/GSD patch is highly effective in preventing pregnancy. Menstrual bleeding pattern was favorable and within the ranges expected of a healthy female population. The patch was well tolerated and treatment compliance was high.

Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population.

OBJECTIVE: To examine the impact of subject characteristics on efficacy as measured by the Pearl Index (PI) in clinical trials and to make study populations similar by matching. METHODS: Our analysis used US data from four large Phase III studies. We compared results from one fertility control patch study with pooled data from three studies with virtually identical design on oral hormonal contraceptives. First, we identified three characteristics that had the most impact on the PI. Second, we used these three variables and matched subjects from the patch study with those from the oral contraceptive (OC) studies. Finally, we calculated the PIs for matched and unmatched subjects from both the patch study and the OC studies. RESULTS: A total of 3706 subjects were included in our analysis. The variables 'Hispanic ethnicity', 'previous pregnancy' and 'previous use of hormonal contraceptives' had the most impact on the PI. The PIs for the matched patch cohort and the matched OC cohort were 2.97 and 2.48, respectively. Those for the unmatched patch cohort and the unmatched OC cohort were 10.17 and 0.90, respectively. CONCLUSION: Subject characteristics strongly influence the PI in clinical studies of hormonal contraceptives. In particular, Hispanic ethnicity, previous pregnancies and no previous use of hormonal contraceptives result in a higher PI. IMPLICATIONS: PIs from different clinical trials cannot be meaningfully compared unless subject characteristics that have most impact on the PI are similar or are made to be similar statistically as we did here by matching.

Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

BACKGROUND: The contraceptive skin patch (CSP) accepted by the U.S. FDA in 2001 includes ethinylestradiol and norelgestromine, whereas the subdermal contraceptive implant (SCI) has etonogestrel and is also approved by the FDA. In Mexico, both are now widely used for contraception but their effects on Mexican population are unknown. The objective of the study was to evaluate if these treatments induce metabolic changes in a sample of indigenous and mestizo Mexican women. METHODS: An observational, prospective, longitudinal, non-randomized study of women between 18 and 35 years of age assigned to CSP or SCI. We performed several laboratory tests: clinical chemistry, lipid profile, and liver and thyroid function tests. Also, serum levels of insulin, C-peptide, IGF-1, leptin, adiponectin, and C reactive protein were assayed. RESULTS: Sixty-two women were enrolled, 25 used CSP (0 indigenous; 25 mestizos) and 37 used SCI (18 indigenous; 19 mestizos). Clinical symptoms were relatively more frequent in the SCI group. Thirty-four contraceptive users gained weight without other clinical significant changes. After 4 months of treatment, significant changes were found in some biochemical parameters in both treatment groups. Most were clinically irrelevant. Interestingly, the percentage of users with an abnormal atherogenic index diminished from 75% to 41.6% after follow-up. CONCLUSIONS: The CSP slightly modified the metabolic variables. Most changes were nonsignificant, whereas for SCI users changes were more evident and perhaps beneficial. Results of this attempt to evaluate the effects of contraceptives in mestizo and native-American populations show that clinical symptoms are frequent in Mexican users of CSP and SCI. Although these medications may affect some metabolic variables, these changes seem clinically irrelevant. Induction of abnormalities in other physiological pathways cannot be ruled out.

Combined oral contraceptives: venous thrombosis.

BACKGROUND: Combined oral contraceptive (COC) use has been associated with venous thrombosis (VT) (i.e., deep venous thrombosis and pulmonary embolism). The VT risk has been evaluated for many estrogen doses and progestagen types contained in COC but no comprehensive comparison involving commonly used COC is available. OBJECTIVES: To provide a comprehensive overview of the risk of venous thrombosis in women using different combined oral contraceptives. SEARCH METHODS: Electronic databases (Pubmed, Embase, Web of Science, Cochrane, CINAHL, Academic Search Premier and ScienceDirect) were searched in 22 April 2013 for eligible studies, without language restrictions. SELECTION CRITERIA: We selected studies including healthy women taking COC with VT as outcome. DATA COLLECTION AND ANALYSIS: The primary outcome of interest was a fatal or non-fatal first event of venous thrombosis with the main focus on deep venous thrombosis or pulmonary embolism. Publications with at least 10 events in total were eligible. The network meta-analysis was performed using an extension of frequentist random effects models for mixed multiple treatment comparisons. Unadjusted relative risks with 95% confidence intervals were reported.Two independent reviewers extracted data from selected studies. MAIN RESULTS: 3110 publications were retrieved through a search strategy; 25 publications reporting on 26 studies were included. Incidence of venous thrombosis in non-users from two included cohorts was 0.19 and 0.37 per 1 000 person years, in line with previously reported incidences of 0,16 per 1 000 person years. Use of combined oral contraceptives increased the risk of venous thrombosis compared with non-use (relative risk 3.5, 95% confidence interval 2.9 to 4.3). The relative risk of venous thrombosis for combined oral contraceptives with 30-35 µg ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. A dose related effect of ethinylestradiol was observed for gestodene, desogestrel, and levonorgestrel, with higher doses being associated with higher thrombosis risk. AUTHORS' CONCLUSIONS: All combined oral contraceptives investigated in this analysis were associated with an increased risk of venous thrombosis. The effect size depended both on the progestogen used and the dose of ethinylestradiol. Risk of venous thrombosis for combined oral contraceptives with 30-35 µg ethinylestradiol and gestodene, desogestrel, cyproterone acetate and drospirenone were similar, and about 50-80% higher than with levonorgestrel. The combined oral contraceptive with the lowest possible dose of ethinylestradiol and good compliance should be prescribed-that is, 30 µg ethinylestradiol with levonorgestrel.

Avaliação do padrão de consumo do 17α – etinilestradiol no município de Santa Maria Madalena, RJ / Evaluation of the pattern of consumption of the 17α - ethinylestradiol in the city of Santa Maria Maddalena, RJ

A presença no meio hídrico de contaminantes orgânicos com atividade estrogênica é um tema que tem gerado crescente preocupação na comunidade científica, uma vez que tais contaminantes são capazes de desencadear efeitos adversos no sistema endócrino de várias espécies. O estrogênio sintético 17α-etinilestradiol (principal componente utilizado em formulações de contraceptivos orais) tem sido apontado como um dos principais compostos responsáveis por provocar tais alterações. O principal objetivo deste estudo foi investigar, através de um questionário, o padrão de consumo do 17α-etinilestradiol presente em contraceptivos orais e medicamentos utilizados na TRH feminina, e estimar o aporte deste estrogênio nos corpos hídricos da área urbana do 1° distrito do município de Santa Maria Madalena. Para o desenvolvimento deste trabalho utilizou-se como metodologia um estudo do tipo inquérito realizado com 325 mulheres de 15 a 59 anos de idade, residentes na área de estudo, no período de setembro a dezembro do ano de 2013. Das 325 mulheres entrevistadas, constatou-se que 95 fazem o uso de contraceptivo oral, sendo que destas, 91 fazem uso de formulações que contêm o 17α-etinilestradiol. Tomando a amostra (...) como estatisticamente representativa da área de estudo, pôde-se extrapolar o valor de consumo do 17 α-etinilestradiol para a população total de mulheres (...) na faixa etária estabelecida. Com base nas informações obtidas a partir da elaboração do presente estudo foi possível estimar que há um considerável aporte desta substância nos corpos hídricos da área urbana do 1° distrito do município de Santa Maria Madalena (16 mg/dia), o que sugere a possibilidade de efeitos adversos à biota aquática local. Uma vez que o presente estudo não encerra a discussão sobre o assunto, ao fim desta dissertação há uma proposição para um trabalho futuro no sentido de se avançar neste tema.

The presence of organic contaminants with estrogenic activity in aquatic environment is a topic with growing concern in scientific community, since those contaminants are capable or triggering adverse effects to the endocrine system of many species. The synthetic estrogen 17α-ethinylestradiol (main compound of formulation of oral contraceptives) is being pointed as one of the main compounds responsible for these effects. The main objective of this study was to investigate, using a survey questionnaire, the consumption pattern of 17α-ethinylestradiol, which is found in oral contraceptives and hormone replacement therapies (HRT), and estimate the input of this estrogen in the water bodies of the 1st district of the city of Santa Maria Madalena, Brazil. In this work, an inquiry method was used at 325 women, ranging from 15 to 59 years old, all residents of the study area, from September to December of 2013. It was noticed that, from that sample, 91 women use formulations which contain 17α-ethinylestradiol. Taking the sample (...) as representative of the study area, an extrapolation could be made to the total of resident women (...) in the same age group. Using the information gathered during the course of this study, it was possible to estimate that there is a considerable input of this substance in the water bodies of the urban area of the 1st district of the city of Santa Maria Madalena (16 mg/day), suggesting the possibility of adverse effects to the local aquatic life. Since this study doesn't put an end to the discussion of this topic, a proposition for future works is made at the final part of this dissertation, aiming for further progress in this subject.

Association of estrogen receptor alpha gene polymorphisms with autonomic modulation of heart rate in users and nonusers of oral contraceptives.

BACKGROUND: This study examined the association between estrogen receptor α gene (ESR1) polymorphisms and blood pressure (BP), heart rate (HR) and autonomic modulation of HR in a sample population. STUDY DESIGN: Two hundred thirty-two young healthy women were selected, and those using oral contraceptives (OC) were compared with nonusers (control group). Short-term HR variability (HRV) was evaluated in both the supine and sitting positions using temporal indices rMSSD [square root of the mean squared differences of successive R-R intervals (RRi) divided by the number of RRi minus one], SDNN (root mean square of differences from mean RRi, divided by the number of RRi) and frequency domain methods. Power spectral components were reported at low frequency (LF) and high frequency (HF) and as LF/HF ratio. ESR1 c.454-397T>C (rs2234693) and c.454-351A>G (rs9340799) polymorphisms were determined by polymerase chain reaction and fragment restriction analysis. RESULTS: The ESR1 T>C and A>G polymorphisms had no effect on HR, rMSSD, SDNN, LF, HF or LF/HF ratio (supine or sitting), independently of OC use. The ESR1 T-A, T-G, C-A and C-G haplotypes were not associated with HR, BP or HRV. CONCLUSIONS: ESR1 variants had no effect on the autonomic modulation of HR in young women users and nonusers of OC and may not be implicated in cardiovascular risk in young women.

Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium.

BACKGROUND: Although the use of combined oral contraceptives (COCs) is associated with an increased risk of arterial and venous thromboembolic events, less is known about the impact of COCs on endothelial function. The present study evaluated the effects on the endothelium of healthy women of combinations of 30 mcg ethinylestradiol (EE)/2 mg chlormadinone acetate (CMA) and 30 mcg EE/150 mcg levonorgestrel (LNG). STUDY DESIGN: Sixty-four healthy women were evaluated, 21 using a nonhormonal contraceptive method (control) and 43 using COCs, randomized to EE 30 mcg /CMA 2 mg or to EE 30 mcg/LNG 150 mcg. Anthropometric parameters, systolic arterial pressure (SAP), diastolic arterial pressure (DAP), ultrasound markers of endothelial function, flow-mediated dilation (FMD) of the brachial artery, intima-media thickness (IMT) and common carotid artery stiffness were measured at randomization and 6 months later. RESULTS: Relative to baseline, EE/CMA users showed a significant reduction in mean DAP at 6 months (p=.02), and EE/LNG users showed a significant increase in mean IMT (p=.02) and a significant reduction in mean FMD (p=.01) at 6 months. DAP at 6 months was significantly lower in COC users than in controls (p=.01). Intergroup evaluations showed that, at 6 months, mean SAP (p=.02) was significantly lower in EE/LNG users than in controls (p=.02) and that mean DAP was significantly lower in EE/CMA (p<.01) and EE/LNG (p=.01) users than in controls. EE/LNG users experienced a mean FMD reduction almost threefold greater than that of EE/CMA users. Compared to controls, EE/LNG users experienced a 7.5-fold greater reduction in mean FMD. CONCLUSIONS: COC containing LNG is associated with more pronounced changes in the FMD and IMT of healthy women than a COC containing CMA and nonhormonal contraception. Further studies are needed to determine whether these differences may lead to higher risk of arterial thromboembolic events.

A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial.

BACKGROUND: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function. STUDY DESIGN: The objective was to evaluate the impact of COC containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP) on the arterial endothelial function, systolic and diastolic blood pressure (SBP and DBP , respectively), heart rate (HR), cardiac output (CO) and total peripheral resistance (TPR) of healthy young women. Of the 71 women in the study, 43 were evaluated before the introduction of COC and after 6 months of its use (case group) and 28, COC nonusers, were assessed for the same parameters at the same time interval (control group). RESULTS: No significant changes in endothelium-dependent and endothelium-independent functions or in measures of SBP, DBP, HR, CO and TPR caused by COC use were observed in the case group (p>.05 for all variables) or in the control group. CONCLUSION: These data suggest COC with 20 mcg EE and 3 mg DRSP does not alter arterial endothelial function or hemodynamic parameters in healthy young women.